Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.

Accepted 2022-09-15 00:00:00 ET · period of report 2022-09-14 · accession 0001104659-22-100486 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2022-09-15	2022-09-14	SUPN	Khattar Jack A.	Pres, CEO, Dir	M - OptEx	$6.40	+4,515	781.5K	+0.6%	+$28.9K
D	2022-09-15	2022-09-14	SUPN	Khattar Jack A.	Pres, CEO, Dir	M - OptEx	$0.00	-5,895	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-09-14	M	D	1,380	$33.75	780,074	D	—	—	(F1) Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. (F2) The price reported in Column 4 is the closing price of the common stock on August 29, 2022, the date of the SAR's exercise, as reported by NASDAQ Stock Market, LLC.
2	Common	Common Stock	2022-09-14	M	A	5,895	$0.00	781,454	D	—	—
3	Derivative	Stock Appreciation Right	2022-09-14	M	D	5,895	$0.00	0	D	$7.90 · — to 2023-02-05	5,895 Common Stock	(F4) The SAR vested in four equal annual installments beginning on February 5, 2014.